peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Bulletin from the extraordinary general meeting of Hansa Medical AB (publ)

22 Dec 2017, 15:00
Regulatory information
On 22 December, 2017, Hansa Medical AB (publ) held an extraordinary general meeting. The following resolutions, among others, were passed at the general meeting.

Approval of the board of directors’ resolution to issue new ordinary shares

The general meeting resolved to approve the board of directors’ resolution, resolved 29 November 2017, to carry out a directed issue of not more than 2,752,526 new ordinary shares, entailing an increase in the share capital of not more than SEK 2,752,526. The right to subscribe for the new ordinary shares in the directed issue shall, with deviation from the shareholders’ pre-emption rights, be granted to a limited number of institutional investors. The reason for the deviation from the shareholders’ pre-emption rights are that the company shall, in a timely manner, be able to secure the capital need for the company’s operations, as well as to broaden the ownership structure of the company with institutional investors.

The subscription price per ordinary share has been determined to SEK 198 per ordinary share. The basis for the subscription price has been determined through a so-called accelerated bookbuilding procedure.

This information was submitted for publication at 3.00 pm on 22 December 2017.

Important information
This announcement is not being made in and copies of it may not be distributed or sent into the United States, the United Kingdom, Canada, Australia or Japan.

The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Hansa Medical AB does not intend to register any of the securities in the United States or to conduct a public offering of the securities in the United States.

This communication does not constitute an offer of the Securities to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the Securities. This communication is being distributed to and is directed only at (i) persons who are outside the United Kingdom or (ii) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents.

For further information, please contact:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: 46707175477

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product, IdeS, is a proprietary antibody-degrading enzyme currently in late- stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications. The company also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing with the objective of treating relapsing autoimmune diseases and cancer. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.